Fosfomycin: what was old is new again

Avent, Minyon; Rogers, Benjamin A.; Cheng, Allen; Athan, Eugene; Francis, Joshua; Roberts, Matthew J.; Paterson, David L.; Harris, Patrick N A

doi:10.1111/imj.14122

Cited by 5 publications

(3 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fosfomycin was discovered in the 1960s and has been used for many years, particularly in the treatment of UTIs. 71 It has a unique mechanism of action, inhibiting UDP-GlcNAc enolpyruvyl transferase, the first step of the synthesis of bacterial cell walls, rendering it useful in the treatment of resistant Gram-negative infections. 71 Indeed, resistance is the driver of the recent increase in its use.…”

Section: Main Therapies Currently Used For Mdr Gram-negative Bacterial Infectionsmentioning

confidence: 99%

“… 71 It has a unique mechanism of action, inhibiting UDP-GlcNAc enolpyruvyl transferase, the first step of the synthesis of bacterial cell walls, rendering it useful in the treatment of resistant Gram-negative infections. 71 Indeed, resistance is the driver of the recent increase in its use. 72 Resistance to fosfomycin itself is most commonly via amino acid replacement or peptidoglycan recycling in the formation of the bacterial wall, and cross-resistance is uncommon.…”

Section: Main Therapies Currently Used For Mdr Gram-negative Bacterial Infectionsmentioning

confidence: 99%

“…73 Fosfomycin is particularly active against E. coli as well as some carbapenem-resistant bacteria. 71 In the ZEUS study, which compared injectable fosfomycin with piperacillin/tazobactam in patients with cUTIs caused mostly by E. coli , fosfomycin was non-inferior in the primary outcome of clinical cure and microbial eradication. 74 E. coli eradication was 100% with fosfomycin.…”

Section: Main Therapies Currently Used For Mdr Gram-negative Bacterial Infectionsmentioning

confidence: 99%

See 2 more Smart Citations

Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections

Bassetti

Garau

2021

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

Microbial resistance is a serious threat to human health worldwide. Among the World Health Organisation’s list of priority resistant bacteria, three are listed as critical—the highest level of concern—and all three are Gram-negative. Gram-negative resistance has spread worldwide via a variety of mechanisms, the most problematic being via AmpC enzymes, extended-spectrum β-lactamases, and carbapenemases. A combination of older drugs, many with high levels of toxicity, and newer agents are being used to combat multidrug resistance, with varying degrees of success. This review discusses the current treatments for multidrug-resistant Gram-negative bacteria, including new agents, older compounds, and new combinations of both, and some new treatment targets that are currently under investigation.

show abstract

Section: Main Therapies Currently Used For Mdr Gram-negative Bacterial Infectionsmentioning

confidence: 99%